Leuprolide

FDA-approved GnRH agonistEstablished

FDA-approved GnRH agonist for prostate cancer, endometriosis, and central precocious puberty. Causes pituitary downregulation after an initial flare. WADA S2 (GnRH analogues).

Calculate Dose

For research use only.

Key Facts

CAS: 53714-56-0
Molecular Weight (MW): 1209.4 g/mol (free base); 1269.4 g/mol (acetate)
Half-life: ~3 hours (immediate-release); depot provides sustained levels
Unit: mcg
Administration Route: Subcutaneous / Intramuscular
Frequency: Daily, monthly, every 3 months, or every 4 months depending on formulation
Last updated: 8/23/2026
Targets: GnRH receptor

Overview

FDA-approved GnRH agonist for prostate cancer, endometriosis, and central precocious puberty. Causes pituitary downregulation after an initial flare. WADA S2 (GnRH analogues).

Protocol

Dosage Range: Varies by indication: 1 mg daily, 7.5 mg monthly, 22.5 mg every 3 months, or 30 mg every 4 months
Frequency: Daily, monthly, every 3 months, or every 4 months depending on formulation
Cycle: Long-term use as prescribed
Administration Route: Subcutaneous / Intramuscular
Reconstitution Guide: Depot formulations require reconstitution per package insert

May vary by vendor concentration and protocol.